Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

智通财经APP讯，智翔金泰(688443.SH)发布公告，近日，公司产品GR1803注射液被国家药品监督管理 局药品审评中心纳入优先审评品种名单。拟定适应症(或功能主治)：本品适用于既往至少接受过三线治 疗(包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体)的复发或难治性多发性骨髓 瘤成人患者。 ...

重庆智翔金泰生物制药股份有限公司 自愿披露关于GR1803注射液纳入优先审评品种 名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）产品 GR1803 注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单，现 将相关情况公告如下： 一、药品基本信息 证券代码：688443 证券简称：智翔金泰 公告编号：2026-002 药品名称：GR1803 注射液 申请人：重庆智翔金泰生物制药股份有限公司 申请日期：2025 年 12 月 26 日 公示日期：2025 年 12 月 29 日 受理号：CXSS2600003 拟定适应症（或功能主治）：本品适用于既往至少接受过三线治疗（包括一 种蛋白酶体抑制剂、一种免疫调节剂和一种抗 CD38 单克隆抗体）的复发或难治 性多发性骨髓瘤成人患者。 优先审评理由：经审核，本申请符合《药品注册管理办法》和《国家药监局 关于发布〈突破性治疗药物审评工作程序（试行）〉等三个文件的公告》（2020 年第 82 号）有关要求，同意按优 ...

每经AI快讯，1月9日，智翔金泰公告称，公司产品GR1803注射液被国家药品监督管理局药品审评中心 纳入优先审评品种名单，拟定适应症为既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患 者。GR1803注射液是一款由公司自主研发的双特异性抗体药物，注册分类为治疗用生物制品1类。新药 上市申请尚需经过多个环节，产品能否成功上市及上市时间存在不确定性。 ...

智翔金泰公告，近日，公司产品GR1803注射液被国家药品监督管理局药品审评中心纳入优先审评品种 名单。GR1803注射液是一款由公司自主研发的双特异性抗体药物，作用靶点为BCMA和CD3，注册分 类为治疗用生物制品1类。 ...

证券之星消息，1月9日生物制品板块较上一交易日上涨1.73%，智翔金泰领涨。当日上证指数报收于 4120.43，上涨0.92%。深证成指报收于14120.15，上涨1.15%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688443 | 智翔金泰 | 32.44 | 11.17% | 11.59万 | | 3.64亿 | | 6168889 | 欧林生物 | 31.02 | 6.82% | 11.06万 | | 3.33亿 | | 300142 | 沃森生物 | 12.12 | 6.32% | 81.49万 | | 9.76亿 | | 000534 | 万泽股份 | 22.67 | 5.05% | 41.77万 | | 9.647 | | 688331 | 荣昌生物 | 96.96 | 4.94% | 8.61万 | | 8.17亿 | | 688180 | 君实生物 | 39.20 | 4.09% | 13.56万 | | 5.20亿 | | ...

维康药业涨超15%，前沿生物、上海谊众涨超10%，联环药业、泓博医药、智翔金泰、诚达药业跟涨。 (本文来自第一财经) 维康药业涨超15%，前沿生物、上海谊众涨超10%，联环药业、泓博医药、智翔金泰、诚达药业跟涨。 (本文来自第一财经) ...

1月9日，A股市场震荡上行，沪指时隔10年重回4100点，A股创新药午后劲爆拉升，截至发稿，20CM创新药新物种——科创创新药ETF汇添富（589120） 涨超3%，反包昨日跌幅！ 科创创新药ETF汇添富（589120）标的指数成分股多数冲高，悦康药业大涨超10%，智翔金泰涨超8%、微芯生物涨超6%，荣昌生物涨超4%，艾力斯、百 利天恒涨超2%，君实生物、百济神州等涨幅居前。 【科创创新药ETF汇添富（589120）标的指数前十大成分股】 | 序号 | 代码 | 名称 | 申万一级行业 | 涨跌幅 | 估自权重 | | --- | --- | --- | --- | --- | --- | | 1 | 688235 | 百济神州-U | 医药生物 | 1.77% | 10.55% | | 2 | 688578 | 艾力斯 | 医药生物 | 2.18% | 9.04% | | 3 | 688506 | 自利天恒 | 医药生物 | 2.84% | 8.82% | | 4 | 688180 | 君实生物-U | 医药生物 | 1.73% | 6.49% | | ਟ | 688266 | 泽璟制药-U | 医药生物 ...

作为智翔金泰自主研发的核心创新产品，GR1803注射液具有独特的技术优势。该药物为BCMA和CD3 双靶点双特异性抗体，基于共同轻链构建，结构与正常单抗分子高度类似，既便于制备工艺开发，又能 减少结构差异导致的免疫原性风险。其核心设计亮点在于非对称亲和力配置，结合BCMA的亲和力(10- 10M)较结合CD3的亲和力(10-8M)高两个数量级，可在有效募集并激活T细胞杀伤肿瘤细胞的同时，减 少T细胞非特异性激活引发的毒副作用，显著提升治疗安全性。此前，该产品已于2024年8月被纳入国 家药监局突破性治疗品种名单。 智翔金泰在公告中提示，GR1803注射液的上市申请尚需经过审评、药品临床试验现场检查、药品生产 现场检查和审批等多个环节，能否成功上市及上市时间存在不确定性。公司将按照相关规定及时披露后 续进展，投资者需谨慎决策、防范投资风险。 中证报中证网讯(王珞)1月9日，重庆智翔金泰生物制药股份有限公司(证券代码：688443，证券简称：智 翔金泰)发布公告称，公司自主研发的治疗用生物制品Ⅰ类创新药GR1803注射液，其境内生产药品注册 上市许可申请已获国家药品监督管理局受理(受理号：CXSS2600003) ...

人民财讯1月9日电，创新药板块午后拉升，维康药业涨超18%，前沿生物、上海谊众涨超10%，联环药 业、泓博医药、智翔金泰、诚达药业跟涨。 ...